EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

A Phase IIa , Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof‐of‐Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease

Mohit Desai, Bhargav Solanki, Manish Hathila, Vikas Asati iD, Suchi Shah, Deven Parmar, Sanjay Vekariya, Kevinkumar Kansagra iD, Mayank Gangwar, Gunjan Kumar, Sudipto Roy iD, Aparna Mukherjee

European Journal of Haematology · 2026-12 · 117 (6) · 1593-1600

DOI: 10.1111/ejh.70296 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Haematology, online erschienen am 25.08.2026. Verfasst von Mohit Desai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Zydus Medical College and Hospital, Dahod, Gujarat, India. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Prolyl-Hydroxylase Inhibitors. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Sickle cell disease (SCD) is an inherited hemoglobin disorder caused by a point mutation in the β ‐globin gene, producing hemoglobin S (HbS). Under hypoxic conditions, HbS polymerizes, leading to rigid, sickled erythrocytes with reduced deformability and increased endothelial adhesion, resulting in vaso‐occlusion and impaired tissue perfusion. Desidustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor, stabilizes HIF and enhances endogenous erythropoietin production. This Phase IIa study evaluated its efficacy and safety in SCD.

Methods

Twenty‐four Indian adults with confirmed SCD (Hb 7–11 g/dL for males, 6.5–11 g/dL for females) were enrolled. Patients were randomized (3:1) across three cohorts receiving 50 mg, 100 mg, or 150 mg desidustat, or placebo, thrice weekly for 8 weeks. The primary endpoint was the proportion achieving ≥ 1 g/dL hemoglobin increase from baseline to Week 8. Secondary endpoints included changes in hemoglobin, hemolysis biomarkers, HbS percentage, transfusion requirement, and vaso‐occlusive events. Safety was assessed via adverse events and clinical parameters.

Results

Among 24 patients (10 males, 14 females; age 25–38 years), Hb response was observed in 50% of patients in the 150 mg cohort versus 16.7% in placebo. Hemoglobin increased dose‐dependently, with reduced LDH levels. No significant changes were noted in HbS or most hemolysis markers. No transfusions or vaso‐occlusive crises occurred. Reported adverse events were mild (nasopharyngitis, polyarthritis, headache), non‐serious, and unrelated to treatment.

Conclusion

Desidustat was well tolerated, with the 150 mg dose showing promising improvements in hemoglobin levels and response rates in SCD patients. Trial Registration CTRI/2024/06/068363

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellProlyl-Hydroxylase InhibitorsAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralBiomarkersDouble-Blind MethodHemoglobin, SickleHemoglobinsTabletsTreatment OutcomeVaso-Occlusive Crises

Substanzen

BiomarkersHemoglobin, SickleHemoglobinsProlyl-Hydroxylase InhibitorsTablets

Autor:innen und Institutionen

  • Zydus Medical College and Hospital, Dahod, Gujarat, India.
  • Silver Touch Hospital, Ahmedabad, Gujarat, India.
  • Sai Krupa Research Centre, Ahmedabad, Gujarat, India.
  • Sri Aurobindo Institute of Medical Sciences, Indore, India.
  • Zydus Research Centre, Clinical R&D, Ahmedabad, Gujarat, India.
  • Zydus Therapeutics Inc., Clinical R&D, Pennington, New Jersey, USA.

ORCID-Profile: Vikas Asati, Kevinkumar Kansagra, Sudipto Roy

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Desai, M., Solanki, B., Hathila, M., Asati, V., Shah, S., Parmar, D., Vekariya, S., Kansagra, K., Gangwar, M., Kumar, G., Roy, S., & Mukherjee, A. (2026). A Phase IIa , Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof‐of‐Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease. European Journal of Haematology, 117(6), 1593-1600. https://doi.org/10.1111/ejh.70296

Vancouver

Desai M, Solanki B, Hathila M, Asati V, Shah S, Parmar D, et al. A Phase IIa , Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof‐of‐Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease. European Journal of Haematology. 2026;117(6):1593-1600. doi:10.1111/ejh.70296

BibTeX
@article{Desai2026,
  author = {Desai, Mohit and Solanki, Bhargav and Hathila, Manish and Asati, Vikas and Shah, Suchi and Parmar, Deven and Vekariya, Sanjay and Kansagra, Kevinkumar and Gangwar, Mayank and Kumar, Gunjan and Roy, Sudipto and Mukherjee, Aparna},
  title = {A Phase IIa , Double Blind, Randomized, Placebo Controlled, Parallel, Multicentre, Proof‐of‐Concept Study to Evaluate the Efficacy and Safety of Desidustat Oral Tablet for Treatment of Sickle Cell Disease},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {6},
  pages = {1593--1600},
  doi = {10.1111/ejh.70296}
}
Kostenlos starten →